The current guidelines by the American Academy of Dermatology (AAD) recommend biologics and systemic treatments like methotrexate, cyclosporine, and newer biologics targeting IL-17, IL-23, and TNF-α for moderate to severe psoriasis. Here, IL17A is linked to psoriasis.